Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.
During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering…
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
In a clinical trial of pediatric patients, tocilizumab proved safe and effective for treating systemic juvenile idiopathic arthritis…
Guidelines address advances in pathophysiology and treatment of systemic juvenile idiopathic arthritis; criteria classify broader spectrum of systemic sclerosis